Comparative Pharmacology
Head-to-head clinical analysis: ARMODAFINIL versus BENZPHETAMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARMODAFINIL versus BENZPHETAMINE HYDROCHLORIDE.
ARMODAFINIL vs BENZPHETAMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Armodafinil is a wakefulness-promoting agent. Its mechanism is unclear but may involve inhibition of dopamine reuptake, leading to increased extracellular dopamine levels. It also affects orexin, histamine, norepinephrine, and GABA pathways.
Benzphetamine is a sympathomimetic amine that acts as a central nervous system stimulant. It primarily works by promoting the release of norepinephrine and dopamine from presynaptic nerve terminals in the brain, which leads to appetite suppression and increased energy expenditure.
Adults: 150-250 mg orally once daily in the morning for narcolepsy or obstructive sleep apnea; 200-400 mg orally once daily for shift work disorder.
25-50 mg orally once daily, may increase by 25 mg increments at weekly intervals; maximum 100 mg/day.
None Documented
None Documented
Clinical Note
moderateArmodafinil + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Armodafinil."
Clinical Note
moderateArmodafinil + Cyclosporine
"The serum concentration of Cyclosporine can be decreased when it is combined with Armodafinil."
Clinical Note
moderateArmodafinil + Aripiprazole
"The serum concentration of Aripiprazole can be decreased when it is combined with Armodafinil."
Clinical Note
moderateCyclophosphamide + Armodafinil
12–15 hours (terminal) in adults; longer in hepatic impairment (e.g., 20–30% increase with cirrhosis).
Benzphetamine has a long elimination half-life of 10-16 hours (up to 20 hours in some individuals). Its active metabolites (amphetamine and methamphetamine) have half-lives of 10-12 hours and 9-11 hours, respectively. Steady state is reached within 3-4 days. The long half-life supports once-daily dosing but carries risk of accumulation with renal impairment.
Renal: ~80% as metabolites (major: armodafinil acid, minor: modafinil sulfone); fecal: <1% unchanged; biliary: negligible.
Primarily renal (approximately 70-90% of the dose excreted unchanged in urine, with the remainder as metabolites including amphetamine and methamphetamine). Fecal excretion is minimal (<5%).
Category C
Category C
CNS Stimulant
CNS Stimulant
"The metabolism of Armodafinil can be decreased when combined with Cyclophosphamide."